Whole-body total lesion glycolysis is an independent predictor in patients with esophageal cancer treated with definitive chemoradiotherapy

• Published in: Radiotherapy and oncology 2018-10, Vol.129 (1), p.161-165
• Main Authors: Takahashi, Noriyoshi, Umezawa, Rei, Takanami, Kentaro, Yamamoto, Takaya, Ishikawa, Youjirou, Kozumi, Maiko, Takeda, Kazuya, Kadoya, Noriyuki, Jingu, Keiichi
• Format: Article
• Language: English
• Subjects: Chemoradiotherapy; Esophageal cancer; Metabolic tumor volume; MTV; TLG; Total lesion glycolysis
• ISSN: 0167-8140; 1879-0887
• DOI: 10.1016/j.radonc.2017.10.019

To determine whether pretreatment whole-body total lesion glycolysis (TLGWB) and metabolic tumor volume (MTVWB) are associated with outcomes in patients with esophageal cancer treated with definitive chemoradiotherapy (dCRT). Ninety patients with stage II or III thoracic esophageal cancer who underwent FDG-PET/CT within 45 days before dCRT between 2005 and 2013 were reviewed. MTV and TLG of the primary lesion (MTVpri and TLGpri) and the sum of MTV and TLG for all lesions (MTVWB and TLGWB) were calculated. Predictors were analyzed using the Cox proportional hazards model. The median follow-up period was 27.7 months. In multivariate analysis, MTVWB > median was an unfavorable predictor for OS (p = 0.027, hazard ratio [HR]: 2.15), LC (p = 0.039, HR: 1.98) and PFS (p = 0.041, HR: 1.96). TLGWB > median was an unfavorable predictor for OS (p = 0.019, HR: 2.26), LC (p = 0.015, HR: 2.36) and PFS (p = 0.014, HR: 2.33). SUVmax was not a predictor, and the HR of TLGWB was higher than that of MTVWB for OS, LC and PFS in multivariate analysis. TLGWB and MTVWB are independent predictors in patients with esophageal cancer.